All lobbying filings

CROSSROADS STRATEGIES, LLC

Lobbying for SANOFI US SERVICES INC. · pharmaceutical manufacturer

Filing 2nd Quarter - Report

2nd Quarter (Apr 1 - June 30) 2025 · New Jersey · House · Senate · $50,000.00 income · posted Jul 20, 2025

Official filing document

Bills named in this filing 2

HR 1
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
S 891
Bipartisan Health Care Act

Lobbying activity 6

Medicare/Medicaid

General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; Drug Pricing; Inflation Reduction Act of 2022 (P.L.117-169) implementation.

Biopharmaceutical innovation and patent policy issues. Bayh-Dole march-in rights policy issues.

Trade (domestic/foreign)

Issues related to pharmaceutical IP, supply chain, and tariffs.

Budget/Appropriations

H.R.1, One Big Beautiful Bill Act, all bio-pharmaceutical related provisions.

Health Issues

Issues related to health care, the Food and Drug Administration (FDA), influenza, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, TRICARE Pharmacy Program (FY2026 National Defense Authorization Act), insulin price cap, VICP Program, and PBM reform; Type One Diabetes (T1D) and military healthcare; Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization; Inflation Reduction Act of 2022 (P.L.117-169) implementation; S.891, Bipartisan Health Care Act; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order.

Taxation/Internal Revenue Code

Issues related to tax reform; R&D tax credit; international taxation; Inflation Reduction Act of 2022 (P.L.117-169) implementation; Section 899; H.R.1, One Big Beautiful Bill Act.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.